Cette première version des orientations evolutives relatives a la prise en charge clinique de la MVE contient quatre nouvelles recommandations concernant l’utilisation de traitements contre la MVE, y compris deux recommandations fortes en faveur de l’utilisation de thérapies à base d’antico...rps monoclonaux. Ce nouveau document est rédigé en vue d’accompagner des soins de support optimisés (oSoC) pour les procédures opérationnelles standards appliquees a la MVE (5, 6). Les orientations evolutives presentent des preuves de haute qualité concernant l’efficacite des traitements contre la MVE et les recommandations de l’OMS relatives leur utilisation.
more
Guide d’urgence provisoire
Emergencias 2021: 33: 42-58
Este manual operativo determina los aspectos y las etapas primordiales de la ampliación programática del tratamiento preventivo de la tuberculosis, y proporciona herramientas de ejecución e instrumentos de trabajo para la adaptación al contexto local, así como indicadores de seguimiento y evalu...ación de la gestión. En él se destacan los elementos clave que deben tenerse en cuenta en la atención al paciente, la planificación nacional estratégica y la movilización de recursos
more
Sci Rep. 2016; 6: 25920. Published online 2016 May 16. doi: 10.1038/srep25920
Guidance for health care workers.
Both the REGN-EB3 and mAb114 are recommended for use in EVD. The two drugs should not be given together. The choice of which monoclonal antibody to use depends on availability, including emerging information about effectiveness.
1st edition
This resource provides practical guidance for front line health workers responsible for the diagnosis, management and care of patients with these two diseases. Published in collaboration with the World Diabetes Foundation
Rreport of a WHO Consultative Meeting Kolkata India 2012
Since the discovery of insulin nearly 100 years ago, advances in diabetes treatments and therapies have transformed the lives of people
with diabetes (PwD), notably reducing the daily burden of its management.
Newer technologies, including those driven by artificial intelligence, have the potentia...l to further improve the quality of life of PwD and help
identify and diagnose people at risk of developing Type 2 diabetes and diabetes-related complications early. However, medical and technological advances alone are not enough to fix the diabetes challenge. It is also critical to acknowledge the complexity and the seriousness of diabetes, its impact on the quality of life and well-being of over 32 million PwD in the EU and the financial burden it represents for health systems and society at large.
more
9th edition; 4th English edition 2020
doi: https://doi.org/10.1101/2020.11.30.20236570
Pre-Print Article